HomeCompareGLS vs MRK

GLS vs MRK: Dividend Comparison 2026

GLS yields 1261.03% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GLS wins by $146401658.74M in total portfolio value
10 years
GLS
GLS
● Live price
1261.03%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$146401658.80M
Annual income
$126,645,570,090,706.19
Full GLS calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — GLS vs MRK

📍 GLS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGLSMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GLS + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GLS pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GLS
Annual income on $10K today (after 15% tax)
$107,187.89/yr
After 10yr DRIP, annual income (after tax)
$107,648,734,577,100.25/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, GLS beats the other by $107,648,734,568,771.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GLS + MRK for your $10,000?

GLS: 50%MRK: 50%
100% MRK50/50100% GLS
Portfolio after 10yr
$73200829.43M
Annual income
$63,322,785,050,252.16/yr
Blended yield
86.51%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

GLS
Analyst Ratings
2
Buy
1
Hold
2
Sell
Consensus: Buy
Altman Z
-7.8
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GLS buys
0
MRK buys
0
No recent congressional trades found for GLS or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGLSMRK
Forward yield1261.03%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$146401658.80M$56.8K
Annual income after 10y$126,645,570,090,706.19$9,798.13
Total dividends collected$144936269.82M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: GLS vs MRK ($10,000, DRIP)

YearGLS PortfolioGLS Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$136,803$126,103.40$11,206$366.19+$125.6KGLS
2$1,758,658$1,612,278.05$12,650$502.35+$1.75MGLS
3$21,252,252$19,370,488.51$14,407$694.19+$21.24MGLS
4$241,506,220$218,766,309.98$16,585$967.82+$241.49MGLS
5$2,581,790,455$2,323,378,799.83$19,342$1,363.89+$2581.77MGLS
6$25,975,389,845$23,212,874,058.16$22,913$1,947.19+$25975.37MGLS
7$246,059,733,136$218,266,066,001.26$27,662$2,823.89+$246059.71MGLS
8$2,195,612,228,432$1,932,328,313,976.66$34,159$4,173.35+$2195612.19MGLS
9$18,463,634,303,105$16,114,329,218,683.17$43,337$6,308.80+$18463634.26MGLS
10$146,401,658,795,029$126,645,570,090,706.19$56,776$9,798.13+$146401658.74MGLS

GLS vs MRK: Complete Analysis 2026

GLSStock

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Full GLS Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this GLS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GLS vs SCHDGLS vs JEPIGLS vs OGLS vs KOGLS vs MAINGLS vs JNJGLS vs ABBVGLS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.